Literature DB >> 3023969

Synergism of v-myc and v-Ha-ras in the in vitro neoplastic progression of murine lymphoid cells.

R C Schwartz, L W Stanton, S C Riley, K B Marcu, O N Witte.   

Abstract

Murine bone marrow was either singly or doubly infected with retroviral vectors expressing v-myc (OK10) or v-Ha-ras. The infected bone marrow was cultured in a system that supports the long-term growth of B-lineage lymphoid cells. While the v-myc vector by itself had no apparent effect on lymphoid culture establishment and growth, infection with the v-Ha-ras vector or coinfection with both v-myc and v-Ha-ras vectors led to the appearance of growth-stimulated cell populations. Clonal pre-B-cell lines stably expressing v-Ha-ras alone or both v-myc and v-Ha-ras grew out of these cultures. In comparison with cell lines expressing v-Ha-ras alone, cell lines expressing both v-myc and v-Ha-ras grew to higher densities, had reduced dependence on a feeder layer for growth, and had a marked increase in ability to grow in soft-agar medium. The cell lines expressing both oncogenes were highly tumorigenic in syngeneic animals. These experiments show that the v-myc oncogene in synergy with v-Ha-ras can play a direct role in the in vitro transformation of murine B lymphoid cells.

Entities:  

Mesh:

Year:  1986        PMID: 3023969      PMCID: PMC367059          DOI: 10.1128/mcb.6.9.3221-3231.1986

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  66 in total

1.  Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma.

Authors:  A ar-Rushdi; K Nishikura; J Erikson; R Watt; G Rovera; C M Croce
Journal:  Science       Date:  1983-10-28       Impact factor: 47.728

2.  Transcriptional activation of the translocated c-myc oncogene in mouse plasmacytomas: similar RNA levels in tumor and proliferating normal cells.

Authors:  E J Keath; A Kelekar; M D Cole
Journal:  Cell       Date:  1984-06       Impact factor: 41.582

3.  Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture.

Authors:  H E Ruley
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

4.  Effect of src infection on long-term marrow cultures: increased self-renewal of hemopoietic progenitor cells without leukemia.

Authors:  D Boettiger; S Anderson; T M Dexter
Journal:  Cell       Date:  1984-03       Impact factor: 41.582

5.  Augmented expression of normal c-myc is sufficient for cotransformation of rat embryo cells with a mutant ras gene.

Authors:  W M Lee; M Schwab; D Westaway; H E Varmus
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

6.  Proteins encoded by v-myc and c-myc oncogenes: identification and localization in acute leukemia virus transformants and bursal lymphoma cell lines.

Authors:  S R Hann; H D Abrams; L R Rohrschneider; R N Eisenman
Journal:  Cell       Date:  1983-10       Impact factor: 41.582

7.  A recovered avian myelocytomatosis virus that induces lymphomas in chickens: pathogenic properties and their molecular basis.

Authors:  P J Enrietto; L N Payne; M J Hayman
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

Review 8.  Translocations among antibody genes in human cancer.

Authors:  P Leder; J Battey; G Lenoir; C Moulding; W Murphy; H Potter; T Stewart; R Taub
Journal:  Science       Date:  1983-11-18       Impact factor: 47.728

9.  ras gene Amplification and malignant transformation.

Authors:  S Pulciani; E Santos; L K Long; V Sorrentino; M Barbacid
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

10.  Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours.

Authors:  O Bernard; S Cory; S Gerondakis; E Webb; J M Adams
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  28 in total

1.  Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis.

Authors:  M W Gramling; C M Eischen
Journal:  Cell Death Differ       Date:  2012-02-03       Impact factor: 15.828

2.  Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src.

Authors:  N Aziz; H Cherwinski; M McMahon
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA.

Authors:  W Tam; D Ben-Yehuda; W S Hayward
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

4.  bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation.

Authors:  A Engelman; N Rosenberg
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

5.  Induction of murine CD5 expression by v-H-ras.

Authors:  T R Weichert; R C Schwartz
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

6.  The 5' noncoding region of the human leukemia-associated oncogene BCR/ABL is a potent inhibitor of in vitro translation.

Authors:  A J Muller; O N Witte
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

7.  Cooperative transforming activities of ras, myc, and src viral oncogenes in nonestablished rat adrenocortical cells.

Authors:  A MacAuley; T Pawson
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

8.  Generation of altered transcripts by retroviral insertion within the c-myb gene in two murine monocytic leukemias.

Authors:  T J Gonda; S Cory; P Sobieszczuk; D Holtzman; J M Adams
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

9.  Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.

Authors:  J C Young; O N Witte
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

10.  Early pre-B-cell transformation induced by the v-fms oncogene in long-term mouse bone marrow cultures.

Authors:  G V Borzillo; C J Sherr
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.